Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Gains from Investment Securities: 2019-2021

Historic Gains from Investment Securities for AC Immune (ACIU) over the last 3 years, with Dec 2021 value amounting to -$14,227.

  • AC Immune's Gains from Investment Securities fell 35.83% to $3.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.8 billion, marking a year-over-year increase of 32373.90%. This contributed to the annual value of -$14,227 for FY2021, which is 120.10% down from last year.
  • Latest data reveals that AC Immune reported Gains from Investment Securities of -$14,227 as of FY2021, which was down 120.10% from $70,794 recorded in FY2020.
  • Over the past 5 years, AC Immune's Gains from Investment Securities peaked at $70,794 during FY2020, and registered a low of -$4.6 million during FY2019.
  • Over the past 3 years, AC Immune's median Gains from Investment Securities value was -$14,227 (recorded in 2021), while the average stood at -$1.5 million.
  • In the last 5 years, AC Immune's Gains from Investment Securities soared by 101.54% in 2020 and then tumbled by 120.10% in 2021.
  • Yearly analysis of 3 years shows AC Immune's Gains from Investment Securities stood at -$4.6 million in 2019, then surged by 101.54% to $70,794 in 2020, then plummeted by 120.10% to -$14,227 in 2021.